GRAIL Inc

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

GRAIL Inc reports revenue growth and narrows sales guidance

GRAIL Inc's Q3 2024 performance reflects positive revenue growth and demand for its Galleri tests, despite ongoing losses.
The company's financial position remains stable with a substantial cash balance, supporting future strategic initiatives and investments.
While challenges persist in achieving profitability, narrowing sales growth guidance and improved cost management signal progress towards long-term sustainability.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

GRAIL, Inc. is a healthcare company. It engages in the development of a technology for early detection of cancer. The company was founded by Jeffrey T. Huber, William H. Rastetter, and Mostafa Ronaghi on September 11, 2015 and is headquartered in Menlo Park, CA.

MENLO PARK, Calif. , Nov. 19, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will participate in the following investor conferences.

GRAIL to Participate in Upcoming Investor Conferences

AstraZeneca

MENLO PARK, Calif. , Nov. 18, 2024  /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the first patient has been tested for eligibility with the investigational GRAIL Non-Small Cell Lung Cancer (NSCLC) ctDNA Assay in the global TROPION-Lung12 Phase 3 study evaluating adjuvant treatment regimens in patients with Stage I adenocarcinoma NSCLC.

GRAIL Announces First Patient Tested With Blood-Based Assay in Global Phase 3 Adjuvant Lung Cancer Study

GRAIL Inc. (NASDAQ:GRAL ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Robert Ragusa - CEO & Director Aaron Freidin - Chief Financial Officer Joshua Ofman - President Harpal Kumar - President, International Business and BioPharma Conference Call Participants Operator Good day, ladies and gentlemen, and welcome to the GRAIL Third Quarter 2024 Earnings Call. [Operator Instructions] Please be advised that this conference call is being recorded.

GRAIL Inc. (GRAL) Q3 2024 Earnings Call Transcript

Galleri Revenue Grew 52% Year-Over-Year to $25.4 Million Commercial Galleri Sales Surpassed 250,000 Tests Since Launch Cash Balance of $853.6 Million Provides Runway Into 2028 MENLO PARK, Calif. , Nov. 12, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the third quarter 2024.

GRAIL Reports Third Quarter 2024 Financial Results

MENLO PARK, Calif. , Nov. 4, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York on Thursday, Nov. 21 at 11:00 a.m.

GRAIL to Present at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

MENLO PARK, Calif. , Oct. 29, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the third quarter 2024 following the close of market on Tuesday, Nov. 12, 2024.

GRAIL to Announce Third Quarter 2024 Financial Results

Study Participants from Veteran Affairs Sites Include a Diverse Population With Toxic Exposure MENLO PARK, Calif. , Oct. 23, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced early results from the REFLECTION study, which aims to understand the real-world experience of the Galleri® multi-cancer early detection (MCED) test in routine clinical settings.

GRAIL Presents Initial Results From REFLECTION Real-World Evidence Study of Galleri® Multi-Cancer Early Detection (MCED) Test at the Early Detection of Cancer Conference

MENLO PARK, Calif. , Oct. 21, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the appointment of Sarah Krevans to its Board of Directors, effective immediately.

GRAIL Appoints Sarah Krevans to Board of Directors

FrontView REIT Inc

GATX

OncoCyte

Cartesian Therapeutics Inc

24/7 Wall St. Insights Insider buying slowed to a trickle ahead of the third-quarter earnings reporting season.

Insider Buying Slows, but Not for 7 These Buyers

AMETEK

Carnival

CrowdStrike

Devon Energy

Eldorado Gold

Emerson Electric

Evolution AB

JFrog

Gap Inc

Inmode Ltd

Intel

iShares U.S. Consumer Goods ETF

Johnson & Johnson

Legend Biotech

Cheniere Energy

NVIDIA

Olaplex Holdings

Ryder System

Regeneron Pharmaceuticals

In September, thirty new analysts joined Seeking Alpha, offering diverse stock picks and insights, from Strong Buy to Strong Sell ratings. Highlighted picks include InMode Ltd., Intel Corporation, and iShares 20+ Year Treasury Bond ETF, each with unique investment theses and strong buy ratings. Analysts' backgrounds range from software engineering to finance, enhancing their stock research with diverse perspectives and methodologies.

Stock Picks From Seeking Alpha's September 2024 New Analysts

Vieu's AI-powered Sales Graph challenges traditional social networks and CRM systems to fast-track enterprise sales pursuits. The Vieu Graph platform indexes billions of relationships and industry-specific data sets to reveal deep social connections and account intelligence that helps build trust with the customer from the first touchpoint. Vieu's AI-powered Sales Graph challenges traditional social networks and CRM systems to fast-track enterprise sales pursuits. The Vieu Graph platform indexes billions of relationships and industry-specific data sets to reveal deep social connections and account intelligence that helps build trust with the customer from the first touchpoint.

Vieu cracks the “holy grail” of B2B sales with AI-powered business network; raises $11m as growth scales

Illumina

GRAIL Inc., spun off from Illumina Inc. in June 2024, faces financial challenges but holds significant growth potential with its Galleri cancer-screening test. Despite a strong balance sheet, GRAIL's Q2 2024 operational loss was $1.64 billion, primarily due to non-cash goodwill and intangible impairments. GRAIL's restructuring plan aims to cut costs, focus on Galleri sales, and extend its cash runway to 2028, supported by Illumina's continued involvement.

GRAIL: Post-Spinoff, Illumina Maintains Control And Incentive To Support Success

Grail's Galleri test detects over 50 cancer types early, potentially saving lives, and is progressing towards FDA approval and broader insurance coverage. The company, a spinoff from Illumina, has significant backing and aims to reduce costs while expanding its market presence and regulatory validation. Despite high cash burn, Grail's strong cash reserves and strategic focus on FDA approval and Medicare reimbursement present substantial upside potential.

GRAIL's Potential Turnaround: Seeking FDA Approval For Galleri

Europe's top court on Tuesday backed U.S. gene sequencing company Illumina's fight against EU antitrust regulators' investigation into its $7.1 billion bid for cancer diagnostic test maker Grail.

EU top court backs Illumina fight against EU probe into Grail deal

MENLO PARK, Calif. , Aug. 30, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 182,223 shares of GRAIL's common stock to 55 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL.

GRAIL ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(c)(4)

Solventum Corporation

Stock spinoffs are a popular corporate strategy for unlocking shareholder value, but one that rarely pays off for investors.

2 Spinoff Stocks Down 16%. Should You Buy Now?

Data Support Clinical Performance of Galleri   to Detect More Aggressive Prostate Cancers MENLO PARK, Calif. , Aug. 29, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL) a healthcare company whose mission is to detect cancer early when it can be cured, today announced that detailed findings of the performance of its Galleri® multi-cancer early detection (MCED) test in prostate cancer were published in JCO Precision Oncology.

Results of GRAIL's Galleri® Multi-Cancer Early Detection Blood Test in Prostate Cancer Published in JCO Precision Oncology

MENLO PARK, Calif. , Aug. 21, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Morgan Stanley 22nd Annual Global Healthcare Conference at 3:20 p.m.

GRAIL to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

GRAIL Inc. (NASDAQ:GRAL ) Q2 2024 Results Conference Call August 13, 2024 4:30 PM ET Company Participants Bob Ragusa - CEO & Director Aaron Freidin - Chief Financial Officer Joshua Ofman - President Conference Call Participants Tejas Savant - Morgan Stanley Sung Ji Nam - Scotiabank Operator Good day, ladies and gentlemen, and welcome to the GRAIL Second Quarter 2024 Earnings Call. At this time, all participants are in listen-only mode.

GRAIL Inc. (GRAL) Q2 2024 Earnings Call Transcript

Cancer test maker Grail said on Tuesday it would reduce existing headcount and planned hires for 2024 by about 30%, as part of its restructuring program.

Grail to cut jobs, planned hires for 2024 by about 30%

Second Quarter Revenue Grew 43%  Year-Over-Year to $32.0 Million Portfolio Prioritization and Corporate Restructure Extends Cash Runway into 2028 MENLO PARK, Calif. , Aug. 13, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the second quarter 2024.

GRAIL Reports Second Quarter 2024 Financial Results and Provides a Strategic Update

MENLO PARK, Calif. , July 31, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the second quarter 2024 following the close of market on Tuesday, Aug. 13, 2024.

GRAIL to Announce Second Quarter 2024 Financial Results

Community Health Network Has Begun Enrollment of the Prospective, Multi-Center Study to Assess the Real-World Clinical Impact of Galleri ®  in Addition to Currently Recommended Cancer Screenings Study Enrollment Includes Focus on Diverse and Underrepresented Populations Costs of Galleri and Related Items and Services for Study Participants Will be Covered by Medicare MENLO PARK, Calif. , July 18, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that the first participant has been enrolled in the REACH/Galleri-Medicare study at Community Health Network, a leading integrated healthcare system in central Indiana with more than 200 sites of care.

GRAIL Announces First Participant Enrolled in REACH Study Evaluating Clinical Impact of Galleri® Multi-Cancer Early Detection (MCED) Test in the Medicare Population

GlaxoSmithKline

ImmunityBio

Discovering and developing a cancer drug that can treat many types of the disease can be extremely lucrative. Consider that one such drug, Merck's (NYSE: MRK ) Keytruda, generated $25 billion in revenue for the pharmaceutical giant last year.

3 Top Cancer Treatment Stocks to Buy Now

WK Kellogg Co

Sandoz Group AG

Stock spinoffs remain popular with companies wanting to unlock shareholder value. By creating spinoff stocks that will trade independently on the market, corporations believe they can narrow their focus to core operations while the newly public company doesn't get lost in the shuffle of its parent's larger objectives.

News for GRAIL Inc Stock (GRAL)